Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report

BACKGROUND Neuroendocrine gastrointestinal tumors (NETs) are rare and have different natural behaviors. Surgery is the gold standard treatment for local disease while radiotherapy has been demonstrated to be ineffective. Poorly differentiated neuroendocrine carcinomas (NECs) represent only 5%-10% of digestive NETS. Due to aggressive growth and rapid metastatic diffusion, early diagnosis and a multidisciplinary approach are mandatory. The role of surgery and radiotherapy in this setting is still debated, and chemotherapy remains the treatment of choice. CASE SUMMARY A 42-year-old male with an ulcerated bleeding rectal lesion was diagnosed with a NEC G3 (Ki67 index > 90%) on May 2015 and initially treated with 3 cycles of first-line chemotherapy, but showed early local progressive disease at 3 mo and underwent sphincter-sparing open anterior low rectal resection. In September 2015, the first post-surgery total-body computed tomography (CT) scan showed an early pelvic disease relapse. Therefore, systemic chemotherapy with FOLFIRI was started and the patient obtained only a partial response. This was followed by pelvic radiotherapy (50 Gy). On April 2016, a CT scan and 18F-fluorodeoxyglucose positron emission tomography imaging showed a complete response (CR) of the pelvic lesion, but pathological abdominal inter-aortocaval lymph nodes were observed. Due to disease progression of abdominal malignant nodes, the patient received radiotherapy at 45 Gy, and finally obtained a CR. As of January 2021, the patient has no symptoms of relapse and no late toxicity after chemotherapy or radiotherapy. CONCLUSION This case demonstrates how a multimodal approach can be successful in obtaining long-term CR in metastatic sites in patients with high grade digestive NECs.

[1]  R. Grützmann,et al.  Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report , 2019, Journal of Medical Case Reports.

[2]  Zhaolin Xu,et al.  Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. , 2019, Current problems in cancer.

[3]  M. Behera,et al.  High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. , 2019, The oncologist.

[4]  D. Ravizza,et al.  Neuroendocrine neoplasms of rectum: A management update. , 2018, Cancer treatment reviews.

[5]  C. Gheorghe,et al.  Metastatic neuroendocrine pancreatic tumor – Case report , 2018, Journal of medicine and life.

[6]  H. Sorbye,et al.  ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas , 2016, Neuroendocrinology.

[7]  P. Rougier,et al.  Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma , 2015, Medicine.

[8]  M. Salhab,et al.  Survival of Patients With Neuroendocrine Carcinoma of the Colon and Rectum: A Population-Based Analysis , 2015, Diseases of the colon and rectum.

[9]  K. Goodman,et al.  A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum , 2014, Annals of Surgical Oncology.

[10]  H. Sorbye,et al.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  P. Ruszniewski,et al.  FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. , 2012, Endocrine-related cancer.

[12]  A. Sauvanet,et al.  Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. , 2010, Endocrine-related cancer.

[13]  H. Thaler,et al.  Neuroendocrine Carcinomas of the Colon and Rectum , 2004, Diseases of the colon and rectum.

[14]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[15]  M. Fjällskog,et al.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors , 2001, Cancer.

[16]  M. Ducreux,et al.  Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin , 1999, British Journal of Cancer.

[17]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.